Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent

被引:85
作者
Hunter, HN
Demcoe, AR
Jenssen, H
Gutteberg, TJ
Vogel, HJ
机构
[1] Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada
[2] Univ Hosp N Norway, Dept Med Microbiol, N-9038 Tromso, Norway
关键词
D O I
10.1128/AAC.49.8.3387-3395.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Lactoferricins are highly basic bioactive peptides that are released in the stomach through proteolytic cleavage of various lactoferrin proteins. Here we have determined the solution structure of human lactoferricin (LfcinH) by conventional two-dimensional nuclear magnetic resonance methods in both aqueous solution and a membrane mimetic solvent. Unlike the 25-residue bovine lactoferricin (LfcinB), which adopts a somewhat distorted antiparallel beta sheet, the longer LfcinH peptide shows a helical content from Gln14 to Lys29 in the membrane mimetic solvent but a nonexistent beta-sheet character in either the N- or C-terminal regions of the peptide. The helical characteristic of the LfcinH peptide resembles the conformation that this region adopts in the crystal structure of the intact protein. The LfcinH structure determined in aqueous solution displays a nascent helix in the form of a coiled conformation in the region from Gln14 to Lys29. Numerous hydrophobic interactions create the basis for the better-defined overall structure observed in the membrane mimetic solvent. The 49-residue LfcinH peptide isolated for these studies was found to be slightly longer than previously reported peptide preparations and was found to have an intact peptide bond between residues Ala11 and Val12. The distinct solution structures of LfcinH and LfcinB represent a novel difference in the physical properties of these two peptides, which contributes to their unique physiological activities.
引用
收藏
页码:3387 / 3395
页数:9
相关论文
共 47 条
[1]   Permeabilizing action of an antimicrobial lactoferricin-derived peptide on bacterial and artificial membranes [J].
Aguilera, O ;
Ostolaza, H ;
Quirós, LM ;
Fierro, JF .
FEBS LETTERS, 1999, 462 (03) :273-277
[2]   Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface [J].
Andersen, JH ;
Jenssen, H ;
Sandvik, K ;
Gutteberg, TJ .
JOURNAL OF MEDICAL VIROLOGY, 2004, 74 (02) :262-271
[3]   Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir [J].
Andersen, JH ;
Jenssen, H ;
Gutteberg, TJ .
ANTIVIRAL RESEARCH, 2003, 58 (03) :209-215
[4]   Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts [J].
Andersen, JH ;
Osbakk, SA ;
Vorland, LH ;
Traavik, T ;
Gutteberg, TJ .
ANTIVIRAL RESEARCH, 2001, 51 (02) :141-149
[5]   LACTOFERRIN IS A LIPID A-BINDING PROTEIN [J].
APPELMELK, BJ ;
AN, YQ ;
GEERTS, M ;
THIJS, BG ;
DEBOER, HA ;
MACLAREN, D ;
DEGRAAFF, J ;
NUIJENS, JH .
INFECTION AND IMMUNITY, 1994, 62 (06) :2628-2632
[6]   BACTERICIDAL EFFECT FOR HUMAN LACTOFERRIN [J].
ARNOLD, RR ;
COLE, MF ;
MCGHEE, JR .
SCIENCE, 1977, 197 (4300) :263-265
[7]   Antibacterial activity of multiple antigen peptides homologous to a loop region in human lactoferrin [J].
Azuma, M ;
Kojima, T ;
Yokoyama, I ;
Tajiri, H ;
Yoshikawa, K ;
Saga, S ;
Del Carpio, CA .
JOURNAL OF PEPTIDE RESEARCH, 1999, 54 (03) :237-241
[8]   IDENTIFICATION OF THE BACTERICIDAL DOMAIN OF LACTOFERRIN [J].
BELLAMY, W ;
TAKASE, M ;
YAMAUCHI, K ;
WAKABAYASHI, H ;
KAWASE, K ;
TOMITA, M .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1121 (1-2) :130-136
[9]  
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[10]   Structure and association of human lactoferrin peptides with Escherichia coli lipopolysaccharide [J].
Chapple, DS ;
Hussain, R ;
Joannou, CL ;
Hancock, REW ;
Odell, E ;
Evans, RW ;
Siligardi, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) :2190-2198